Expertise in
9
conditions

Dr. Donald S. Marks

Neurology
45 Resnik Road, Suite 205, 
Plymouth, MN 
Accepting New Patients
Expertise in
9
conditions
45 Resnik Road, Suite 205, 
Plymouth, MN 

Overview

Donald Marks is a Neurologist practicing medicine in Plymouth, Minnesota.

Dr. Marks is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Cerebellar Degeneration, Memory Loss, and Movement Disorders.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 13 clinical trials. Dr. Marks is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in MA

Hospital Affiliations

Beth Israel Deaconess Hospital Plymouth
Nantucket Cottage Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Donald S Marks MD PC
45 Resnik Road, Suite 205, Plymouth, MN 02360

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Nicotine Transdermal Patch
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

3 Total Publications

Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease.
Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease.
Journal: Acta neuropathologica
Published: March 03, 2026
Similar Doctors
Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

Office

55 Fruit St # 9, 
Boston, MA 
 (33.8 miles away)
617-724-8770
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Plotkin is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Plotkin is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis, and Acoustic Neuroma. Dr. Plotkin is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required
Before you request

Dana-Farber Cancer Institute, Center For Neuro-Oncology

450 Brookline Avenue, 
Boston, MA 
 (33.5 miles away)
617-632-2166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Wen is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Wen is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Wen is board certified in Neurology and Neuro-Oncology. Dr. Wen is currently accepting new patients.

Expertise in
77
conditions
Expertise in
77
conditions
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (33.8 miles away)
617-726-3216
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Schmahmann is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Schmahmann is highly rated in 77 conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia, Acute Cerebellar Ataxia, Olivopontocerebellar Atrophy, Posterior Fossa Decompression, and Gastrostomy. Dr. Schmahmann is currently accepting new patients.

Frequently Asked Questions about Dr. Donald S. Marks

How do I make an appointment with Dr. Donald S. Marks?

You can book an appointment with Dr. Donald S. Marks by calling their office at 508-746-5060. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Donald S. Marks a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Donald S. Marks is classified as an Distinguished expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Donald S. Marks specialize in?

While Dr. Donald S. Marks is a Neurology, they have specific expertise in Alzheimer's Disease, Cerebellar Degeneration, and Memory Loss. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Donald S. Marks participate in research or clinical trials?

Yes. Dr. Donald S. Marks has published 3 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Dr. Donald S. Marks's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Donald S. Marks accept my insurance?

Dr. Donald S. Marks accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 508-746-5060 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Marks's expertise for a condition
ConditionClose
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile